Travere Therapeutics Q2 product sales rise on FILSPARI demand
TVTX•Outlook
- Travere expects topline data from the pegtibatinase Phase 3 HARMONY Study in 2H 2027.
- The company plans to initiate a Phase 4 FILSPARI study in FSGS patients of African ancestry in 2H 2026.
- Travere anticipates data presentations from the SPARX Study in recurrent IgAN or FSGS in 2027.
Overview
- U.S. biopharma's Q2 net product sales rose 70% yr/yr, driven by FILSPARI growth.
- The company posted a Q2 net loss after a $40 mln inducement expense tied to convertible note repurchases.
- Travere in-licensed civorebrutinib, expanding its rare kidney disease pipeline.
Result drivers
- FILSPARI sales growth - Co said U.S. net product sales of FILSPARI rose 96% yr/yr, driven by early FSGS launch and continued IgAN growth.
- Commercial investment - Higher SG&A expenses were attributed to commercial investments supporting FILSPARI launch in FSGS and ongoing IgAN commercialization.
- R&D spending - Increased R&D expenses were primarily due to advancement of the Phase 3 HARMONY Study and manufacturing of pegtibatinase.
Key details and analyst coverage
Related News
Champion Homes FY27 Q1 EPS rises to $0.89; net sales increase 1.3% to $710.2 million
SKY•
DigitalBridge Q2 FY26 net income attributable to common stockholders swings to USD 212.68 million; revenue turns positive to USD 508.68 million
DBRG•
